Publications by authors named "W D Figg"
The translation of basic drug discoveries from laboratories to clinical use presents substantial challenges. Factors such as insufficient funding, misdirected project focus, and inability to understand a drug's limitations or strengths contribute to the difficulty of this process. To address these issues, the National Institutes of Health (NIH) has established various resources dedicated to streamlining drug development.
View Article and Find Full Text PDFObjective: To investigate the effects of oral baricitinib on ocular surface disease (OSD) in patients with chronic graft-versus-host disease (cGVHD).
Design: Prospective phase 1 to 2 single institution trial.
Subjects: Eighteen patients with ocular graft-versus-host-disease (oGVHD) and systemic steroid-refractory cGVHD.
Article Synopsis
- Clinical trials for cancer treatments should be based on strong scientific understanding and proven drug effectiveness in relevant disease models.
- This study examines the effects of four small-molecule drugs on lymphoma cell lines, revealing that synergistic combinations effectively induce cell death (apoptosis) in a way that mimics actual drug exposure in patients.
- The findings suggest that in vitro drug screening can help identify effective drug combinations that leverage their synergistic effects to tackle the complexity of human cancers, especially in diverse genetic lymphoma models.
Small-molecule disruption of androgen receptor-dependent chromatin clusters.
Proc Natl Acad Sci U S A
November 2024
Sustained androgen receptor (AR) signaling during relapse is a central driver of metastatic castration-resistant prostate cancer (mCRPC). Current AR antagonists, such as enzalutamide, fail to provide long-term benefit for the mCRPC patients who have dramatic increases in AR expression. Here, we report AR antagonists with efficacy in AR-overexpressing models.
View Article and Find Full Text PDF